Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema ... 40% graft survival rate at 20 years. (Lancet Diabetes & Endocrinology) ...

The market overreacted to CagriSema trial results, causing a 20% stock drop, despite promising 22.7% weight loss results. I believe the market's reaction to CagriSema is disproportionate and doesn ...

defendants created the false impression that they possessed reliable information pertaining to Novo Nordisk's projected successful outcome of Novo Nordisk's phase 3 CagriSema study on obesity ...

The firm sees a “reasonable” valuation at current share levels and views the upcoming CagriSema readout from Novo Nordisk (NVO) as a “positively skewed catalyst.” Published first on TheFly ...

On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial, which determined that the Company's CagriSema product had achieved a weight loss average of only 22.7% after 68 weeks.

Novo Nordisk's drastic selloff may be attributed to the management overpromising CagriSema's 25% weight loss target along with the decelerating top-line growth trend. The company now faces ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release ...

CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial ...

defendants created the false impression that they possessed reliable information pertaining to Novo Nordisk’s projected successful outcome of Novo Nordisk’s phase 3 CagriSema study on obesity ...

The company’s stock declined approximately 20% following clinical trial results for its obesity drug, CagriSema. The trial showed a weight reduction of 22.7%, slightly below the expected 25% ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

AMD’s data center revenue surged 69%, driving Q4 earnings and revenue beats. Tesla’s Germany sales dropped 60%, raising concerns over Elon Musk’s political impact. Brand New Membership Level ...